Nanotechnology Applications for Cancer Chemotherapy

Sanyog Jain is an Associate Professor of Pharmaceutics at the Centre for Pharmaceutical Nanotechnology, National Institute of Pharmaceutical Education and Research (NIPER), India. His research focuses in the areas of nanomedicine and advanced drug delivery. His laboratory has been actively engaged with the design and evaluation of myriad of nanostructured drug delivery vehicles, a few of which are already at advanced stage of development. Kaisar Raza is an Assistant Professor at the Department of Pharmacy, Central University of Rajasthan, Ajmer, India. His research focuses on the development of nanoscale systems for the improvement of cancer chemotherapy, brain delivery, dermal and transdermal assimilation and oral bioavailability of many of drugs Apart from routine nanotechnological interventions, his expertise lies in pharmacokinetics and quality-by-design. Ashish Kumar Agrawal is an Assistant Professor, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (Banaras Hindu University), India. Dr. Agrawal has a PhD in Pharmaceutical Technology (Formulation) from the National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab (India). He later joined James Graham Brown Cancer Center, University of Louisville, Kentucky (USA) as a Postdoc Fellow. His research interests include targeted and controlled drug delivery by using nanotechnology based approaches, development of vesicular and particulate nanocarriers for various biomedical applications, and protein and peptide delivery through alternative routes. Dr. Ankur Vaidya did his graduation, post-graduation and PhD from Dept. of Pharmaceutical Sciences, Dr. H. S. Gour University, Sagar (M.P.) in 2004, 2008 and 2013 respectively. Dr. Vaidya has a teaching and research experience of many years and is currently working as Asst. Professor in Faculty of Pharmacy UPUMS, Saifai, Etawah (U.P.) India. Dr. Ankur has a key research interest in discovery of new anticancer agents with novel targets and published dozens outstanding publications in various International journals. Dr Vaidya has credited as reviewer of international journals of repute in the field of Pharmaceutical sciences. Dr. Ankur has guided several postgraduate theses and was also the recipient of AICTE-NDF (National Doctorate Fellowship) fellowship for PhD research project. Dr. Vaidya has published nternational book chapters, one International book authored and 1 national book. Dr. Ankur has participated/presented in various National and International conferences.

• 1. Basic pathology and etiology of tumor and its microenvironment2. EPR effect and its implication in passive targeting of nanocarrier to the tumor3. pH sensitive carriers as delivery to tumor4. Temperature sensitive carrier temperature directed tumor cell eradication5. Magnetically responsive delivery into tumor environment6. Ligands used for tumor targeting7. Therapy targeting angiogenic potential of tumor8. Immunotherapy of cancer9. Chemical linkers: Potential approach to target tumor10. Cell penetrating peptide in cancer targeting11. Inorganic nanoparticles: A new avenue in improving diagnostics12. Development of photodynamic cancer therapy13. Therapeutics based on small interfering RNAs (siRNA)14. Aptamer conjugates: A new avenue15. Application of cancer stem cells in improving therapeutics16. Targeting breast cancer17. Lung cancer: improving efficacy and reducing side effects18. Colorectal cancer: and its targeting19. Hepatic cancer targeting20. Solid tumor: Addressing the problems associated21. Pancreatic cancer: Removing extracellular matrix barrier in delivery22. Targeting to the CNS: Approach for brain tumor23. Metastatic cancer: How one can address the therapeutic challenge24. Prostate cancer: Delivery aspect and prospect25. Leukemia: trends in treatment and how close we have achieved eradication26. Tumor imaging and its application in tumor targeted drug delivery27. 2D and 3D cell culture: Getting close to mimicking tumor microenvironment in vitro28. In vivo animal model for cancer: What have we learnt from chemical induced and xenograft models29. Nanosystem: regulatory aspects, clinical development and market potential